Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





First COVID-19 Antibody Test Receives FDA EUA for Use with Home Collected Dried Blood Spot Samples

By LabMedica International staff writers
Posted on 08 Apr 2021
The US Food and Drug Administration (FDA) has granted Emergency Use Authorization (EUA) for the first antibody test for use with home collected dried blood spot samples.

Symbiotica, Inc. More...
(Vacaville, CA, USA) has received FDA EUA for its COVID-19 Self-Collected Antibody Test System for prescription use with a fingerstick dried blood sample that is self-collected by an individual age 18 years or older or collected by an adult from an individual five years of age and older. Samples collected at home are then sent to a Symbiotica laboratory for analysis.

The test is intended to aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection. The COVID-19 Self-Collected Antibody Test System is not meant to be used to diagnose or exclude acute SARS-CoV-2 infection.

“The authorization of the first prescription use, home collection antibody test will play an important role in helping health care professionals identify individuals who have developed an adaptive immune response from a recent or prior COVID-19 infection,” said Jeff Shuren, M.D., J.D., director of the FDA’s Center for Devices and Radiological Health.”

Related Links:
Symbiotica, Inc.


Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Online QC Software
Acusera 24•7
New
POC Immunoassay Analyzer
Procise DX
New
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Researchers identified blood-based genomic signatures characteristic of inflammatory breast cancer (photo courtesy of Shutterstock)

Liquid Biopsy Biomarkers Distinguish Inflammatory Breast Cancer and Support Monitoring

Inflammatory breast cancer is among the most aggressive forms of breast malignancy and remains challenging to diagnose and monitor. Obtaining tumor tissue can be difficult, and standard genome and RNA... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.